Uday Saxena

Indian Institute of Technology Hyderabad — India

Medicine · Health Sciences

28h-index2.7kcitations86works0.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes, Cardiovascular Risks, and Lipoproteins(17), Lipoproteins and Cardiovascular Health(16), Lipid metabolism and disorders(16), Atherosclerosis and Cardiovascular Diseases(12), SARS-CoV-2 and COVID-19 Research(8)

Publications86 total

An Indian Diet–Relevant Rat Screening Model for Hypertriglyceridemia-Associated Fatty Liver
2026Open Access
NexaSweet® Attenuates DSS⍰Induced Colitis and Preserves Colon Architecture in Male BALB/c Mice
2026Open Access
UT-018, A Stem-Cell Chemoattractant Nutraceutical for intestinal Healing in DSS-Induced Colitis
2025Open Access
Novel nanobody drug conjugate as a prophylactic or therapeutic against SARS-CoV-2 infection in mice
Biochemical and Biophysical Research Communications·2025· 2 cited
Human like severe hypertriglyceridemia in a high fat fed chicken model
2024· 1 citedOpen Access
Robust acidic pH and digestive enzyme stability of anti-SarsCov2 IgY antibodies: Implications for treatment of viral transmission thru gastrointestinal, ocular, nasal and skin tissues
2023· 2 citedOpen Access
Metformin an anti-diabetic drug, possess ACE-2 receptor-SARS-Cov-2 RBD binding antagonist activity, anti-inflammatory and cytokine inhibitory properties suitable for treatment of COVID-19
2023Open Access
Targeted neutralizing IgY antibodies against SGLT1 glucose transporter reduce glucose uptake and improve glycemic profile in vivo
2023Open Access
An Anti-diabetic Nutraceutical enhances muscle cell glucose uptake of cardiometabolic drugs
2023Open Access
Suppression of insulin stimulated muscle glucose uptake by non-caloric sweetener sucralose and its reversal by an antidiabetic nutraceutical supplement
2022Open Access
Nutraceutical supplement targeting multiple molecular steps synergistically enhances muscle glucose uptake and improves in vivo oral glucose disposal
2022· 2 citedOpen Access
An Integrated 3D bioprinted “disease in a dish” lung cancer model to simultaneously study drug efficacy, toxicity and metabolism
2022· 1 citedOpen Access
A 3-Dimensional bioprinted human gut-liver axis model for studying Alcoholic Liver Disease
2022· 1 citedOpen Access
Differential Activity of Repurposed Drugs as Receptor Binding Domain Antagonists for <i>Omicron</i> and Native Strains of SarsCov2
2022· 1 citedOpen Access
Advances in Animal Models and Cutting-Edge Research in Alternatives: Proceedings of the Second International Conference on 3Rs Research and Progress, Hyderabad, 2021
Alternatives to Laboratory Animals·2022· 5 cited
Edible formulations of chicken egg derived IgY antibodies neutralize SarsCoV2 Omicron RBD binding to human ACE2
2022· 1 citedOpen Access
Building Human In Vitro 3D Models to Replace Animal Studies During Drug Discovery Research: Scientific, Ethical and Regulatory Considerations
2022· 3 cited
Preparation of ingestible antibodies to neutralize the binding of SarsCoV2 RBD (receptor binding domain) to human ACE2 Receptor
2021· 15 citedOpen Access
Corrigendum to: Double PEGylation Significantly Improves Pharmacokinetic Properties of Irinotecan Containing Nanoparticles in a Zebrafish Model
Current Nanomedicine·2021Open Access
Identification of SGLT2 inhibitor Ertugliflozin as a treatment for COVID-19 using computational and experimental paradigm
2021· 3 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Ira J. Goldberg(12), Sivaram Pillarisetti(7), Erika Ferguson(7), Patricia K. Somers(6), Russell R. Hill(6), Joachim Wölle(6), Charles Q. Meng(5), Lee K. Hoong(5), Roger S. Newton(5), Michal Klein(4), Martin A. Wasserman(4), Russell M. Medford(4), Bruce J. Auerbach(4), Xiaoxiang Zheng(4), Pushkar Kulkarni(4), Raghavender Medishetti(4), C L Bisgaier(3), Cynthia L. Sundell(3), Ki‐Ling Suen(3), Charles Kunsch(3)